Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

EROS-mediated control of NOX2 and P2X7 biosynthesis

Lyra O. Randzavola, Paige M. Mortimer, Emma Garside, Elizabeth R. Dufficy, Andrea Schejtman, Georgia Roumelioti, Lu Yu, Mercedes Pardo, Charlotte Tolley, Cordelia Brandt, Katherine Harcourt, Mike Nahorski, Geoff Woods, James C. Williamson, Shreehari Suresh, John M. Sowerby, Will M. Rae, Paul J. Lehner, Jyoti Choudhary, Simon Clare, Anneliese Speak, Giorgia Santilli, Francesca Magnani, Kenneth G. C. Smith, David C. Thomas
doi: https://doi.org/10.1101/2021.09.14.460103
Lyra O. Randzavola
1Department of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, W12 0NN, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paige M. Mortimer
1Department of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, W12 0NN, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma Garside
1Department of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, W12 0NN, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth R. Dufficy
2The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, CB2 0SP, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Schejtman
3Molecular Immunology Unit, UCL Great Ormond Street Institute of Child Health, London, WC1N 1EH, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georgia Roumelioti
4Functional Proteomics, Division of Cancer Biology, Institute of Cancer Research, London, SW7 3RP, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lu Yu
4Functional Proteomics, Division of Cancer Biology, Institute of Cancer Research, London, SW7 3RP, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mercedes Pardo
4Functional Proteomics, Division of Cancer Biology, Institute of Cancer Research, London, SW7 3RP, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte Tolley
5Wellcome Trust Sanger Institute, Hinxton, CB10 1RQ, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cordelia Brandt
5Wellcome Trust Sanger Institute, Hinxton, CB10 1RQ, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine Harcourt
5Wellcome Trust Sanger Institute, Hinxton, CB10 1RQ, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike Nahorski
6Cambridge Institute of Medical Research, University of Cambridge, Cambridge, CB2 0XY, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoff Woods
6Cambridge Institute of Medical Research, University of Cambridge, Cambridge, CB2 0XY, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James C. Williamson
2The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, CB2 0SP, United Kingdom
7Cambridge Institute of Therapeutic Immunology & Infectious Disease, Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus, Cambridge, CB2 0AW, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shreehari Suresh
2The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, CB2 0SP, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John M. Sowerby
2The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, CB2 0SP, United Kingdom
7Cambridge Institute of Therapeutic Immunology & Infectious Disease, Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus, Cambridge, CB2 0AW, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Will M. Rae
2The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, CB2 0SP, United Kingdom
7Cambridge Institute of Therapeutic Immunology & Infectious Disease, Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus, Cambridge, CB2 0AW, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul J. Lehner
2The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, CB2 0SP, United Kingdom
7Cambridge Institute of Therapeutic Immunology & Infectious Disease, Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus, Cambridge, CB2 0AW, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jyoti Choudhary
4Functional Proteomics, Division of Cancer Biology, Institute of Cancer Research, London, SW7 3RP, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Clare
5Wellcome Trust Sanger Institute, Hinxton, CB10 1RQ, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anneliese Speak
5Wellcome Trust Sanger Institute, Hinxton, CB10 1RQ, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giorgia Santilli
3Molecular Immunology Unit, UCL Great Ormond Street Institute of Child Health, London, WC1N 1EH, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesca Magnani
8Department of Biology and Biotechnology, University of Pavia, Pavia, 27100, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth G. C. Smith
2The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, CB2 0SP, United Kingdom
7Cambridge Institute of Therapeutic Immunology & Infectious Disease, Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus, Cambridge, CB2 0AW, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C. Thomas
1Department of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, W12 0NN, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Summary

EROS (Essential for Reactive Oxygen Species) protein is indispensable for expression of the gp91phox-p22phox heterodimer of the phagocyte NADPH oxidase. EROS deficiency in humans causes the severe immunodeficiency, chronic granulomatous disease (CGD), but its mechanism of action remains unknown. We elucidate the role of EROS, showing it acts at the earliest stages of gp91phox maturation. It binds the immature 58kDa gp91phox directly, interacting with the OST glycosylation machinery and prevents gp91phox degradation. EROS also regulates the purine receptors P2X7 and P2X1 through direct interactions and P2X7 is almost absent in EROS deficiency. Accordingly, lack of EROS results in markedly abnormal P2X7 signalling, inflammasome activation and T cell responses. The loss of both ROS and P2X7 signalling leads to resistance to influenza infection. Our work identifies EROS as a highly selective chaperone for key proteins in innate and adaptive immunity and a rheostat for immunity to infection. It has profound implications for our understanding of immune physiology, immunodeficiency and gene therapy.

Competing Interest Statement

The authors have declared no competing interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 15, 2021.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
EROS-mediated control of NOX2 and P2X7 biosynthesis
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
EROS-mediated control of NOX2 and P2X7 biosynthesis
Lyra O. Randzavola, Paige M. Mortimer, Emma Garside, Elizabeth R. Dufficy, Andrea Schejtman, Georgia Roumelioti, Lu Yu, Mercedes Pardo, Charlotte Tolley, Cordelia Brandt, Katherine Harcourt, Mike Nahorski, Geoff Woods, James C. Williamson, Shreehari Suresh, John M. Sowerby, Will M. Rae, Paul J. Lehner, Jyoti Choudhary, Simon Clare, Anneliese Speak, Giorgia Santilli, Francesca Magnani, Kenneth G. C. Smith, David C. Thomas
bioRxiv 2021.09.14.460103; doi: https://doi.org/10.1101/2021.09.14.460103
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
EROS-mediated control of NOX2 and P2X7 biosynthesis
Lyra O. Randzavola, Paige M. Mortimer, Emma Garside, Elizabeth R. Dufficy, Andrea Schejtman, Georgia Roumelioti, Lu Yu, Mercedes Pardo, Charlotte Tolley, Cordelia Brandt, Katherine Harcourt, Mike Nahorski, Geoff Woods, James C. Williamson, Shreehari Suresh, John M. Sowerby, Will M. Rae, Paul J. Lehner, Jyoti Choudhary, Simon Clare, Anneliese Speak, Giorgia Santilli, Francesca Magnani, Kenneth G. C. Smith, David C. Thomas
bioRxiv 2021.09.14.460103; doi: https://doi.org/10.1101/2021.09.14.460103

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Immunology
Subject Areas
All Articles
  • Animal Behavior and Cognition (6101)
  • Biochemistry (13883)
  • Bioengineering (10580)
  • Bioinformatics (33623)
  • Biophysics (17327)
  • Cancer Biology (14392)
  • Cell Biology (20386)
  • Clinical Trials (138)
  • Developmental Biology (10994)
  • Ecology (16223)
  • Epidemiology (2067)
  • Evolutionary Biology (20531)
  • Genetics (13527)
  • Genomics (18822)
  • Immunology (13949)
  • Microbiology (32538)
  • Molecular Biology (13547)
  • Neuroscience (70958)
  • Paleontology (533)
  • Pathology (2222)
  • Pharmacology and Toxicology (3781)
  • Physiology (5961)
  • Plant Biology (12170)
  • Scientific Communication and Education (1826)
  • Synthetic Biology (3406)
  • Systems Biology (8246)
  • Zoology (1875)